Podcast: Jim Zukin Discusses the Reasonable Basis Review (“RBR”) for SPACs
by Kristi Marvin on 2022-07-29 at 8:33am

We spoke with Jim Zukin, the CEO & Chairman of Zukin Certification Services, and former Co-Founder of Houlihan Lokey, about his new product  – the Reasonable Basis Review, or “RBR”.

The Reasonable Basis Review is intended to help SPAC sponsors follow SEC guidance as it relates to financial projections, but also allow their target companies to have financial projections reviewed and validated by a trusted third-party.

Jim goes into why he thinks the RBR will be widely adopted by SPACs as a result of the current SEC SPAC rule proposal. But, he also believes the RBR will have a large presence in the wider M&A landscape.

Give it a listen


 

 

Recent Posts
by Nicholas Alan Clayton on 2024-12-26 at 8:07am

At the SPAC of Dawn (UPDATED) It was a slow start to the day after the Christmas holiday, especially because the SEC was “experiencing technical difficulties” this morning. That makes for a slow news day. Other than that, we hope everyone had a great holiday and is easing back into the work flow. Deals and...

by Nicholas Alan Clayton on 2024-12-24 at 2:07pm

Aimei Health Technology II Co., Ltd (NASDAQ:AHJKU) has filed for a $60 million SPAC ostensibly to pair up with a small cap biotech or medical device target, but its team’s experience both in SPACs and beyond suggest the vehicle will be open to a broad set of potential targets. It is the first SPAC to...

by Nicholas Alan Clayton on 2024-12-24 at 8:13am

At the SPAC of Dawn The markets got to open one stocking early yesterday, but it was mostly coal as it showed durable goods orders had declined by more than twice as much as expected to -1.1% in November. It wasn’t all signs of naughtiness, however. Amid the numbers that came public one day earlier...

by Nicholas Alan Clayton on 2024-12-23 at 3:40pm

Copley Acquisition Corp has filed to raise a $150 million SPAC to hunt for a technology or lifestyle target in either the Asia Pacific or North America regions. The new S-1 also advances underwriter Clear Street in the league tables as it has backed two of the three latest SPACs to file in December, and...

by Kristi Marvin on 2024-12-23 at 10:52am

Translational Development Acquisition Corp. (NASDAQ: TDACU) announced the pricing of its $150 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “TDACU”, Monday, December 23, 2024. The new SPAC intends to take a generalist approach in searching for a business combination, but intend to focus on industries that...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved